236 related articles for article (PubMed ID: 16886636)
1. Anticancer versus antigrowth activities of three analogs of the growth-inhibitory peptide: relevance to physicochemical properties.
Mizejewski GJ; Eisele L; Maccoll R
Anticancer Res; 2006; 26(4B):3071-6. PubMed ID: 16886636
[TBL] [Abstract][Full Text] [Related]
2. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.
Caceres G; Dauphinee MJ; Eisele LE; MacColl R; Mizejewski GJ
Anticancer Res; 2002; 22(5):2817-20. PubMed ID: 12530002
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogenic and anticancer activities of peptides derived from the active site of alpha-fetoprotein.
Joseph LC; Bennett JA; Kirschner KN; Shields GC; Hughes J; Lostritto N; Jacobson HI; Andersen TT
J Pept Sci; 2009 Apr; 15(4):319-25. PubMed ID: 19189271
[TBL] [Abstract][Full Text] [Related]
4. Review and proposed action of alpha-fetoprotein growth inhibitory peptides as estrogen and cytoskeleton-associated factors.
Mizejewski G; Smith G; Butterstein G
Cell Biol Int; 2004; 28(12):913-33. PubMed ID: 15566961
[TBL] [Abstract][Full Text] [Related]
5. Review of Growth Inhibitory Peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis.
Muehlemann M; Miller KD; Dauphinee M; Mizejewski GJ
Cancer Metastasis Rev; 2005 Sep; 24(3):441-67. PubMed ID: 16258731
[TBL] [Abstract][Full Text] [Related]
6. Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis.
Mizejewski GJ; Muehlemann M; Dauphinee M
Chemotherapy; 2006; 52(2):83-90. PubMed ID: 16498241
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of anti-cancer growth inhibitory peptides derived from human alpha-fetoprotein: review of an International Multi-Center Collaborative Study.
Mizejewski GJ; Mirowski M; Garnuszek P; Maurin M; Cohen BD; Poiesz BJ; Posypanova GA; Makarov VA; Severin ES; Severin SE
J Drug Target; 2010 Sep; 18(8):575-88. PubMed ID: 20151941
[TBL] [Abstract][Full Text] [Related]
8. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics.
Mizejewski GJ; MacColl R
Mol Cancer Ther; 2003 Nov; 2(11):1243-55. PubMed ID: 14617798
[TBL] [Abstract][Full Text] [Related]
9. Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties.
Eisele LE; Mesfin FB; Bennett JA; Andersen TT; Jacobson HI; Vakharia DD; MacColl R; Mizejewski GJ
J Pept Res; 2001 Jun; 57(6):539-46. PubMed ID: 11437957
[TBL] [Abstract][Full Text] [Related]
10. Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization.
DeFreest LA; Mesfin FB; Joseph L; McLeod DJ; Stallmer A; Reddy S; Balulad SS; Jacobson HI; Andersen TT; Bennett JA
J Pept Res; 2004 May; 63(5):409-19. PubMed ID: 15140158
[TBL] [Abstract][Full Text] [Related]
11. Structure and function of a custom anticancer peptide, CB1a.
Wu JM; Jan PS; Yu HC; Haung HY; Fang HJ; Chang YI; Cheng JW; Chen HM
Peptides; 2009 May; 30(5):839-48. PubMed ID: 19428759
[TBL] [Abstract][Full Text] [Related]
12. Substance P analogs containing alpha,alpha-dialkylated amino acids with potent anticancer activity.
Prasad S; Mathur A; Jaggi M; Singh AT; Mukherjee R
J Pept Sci; 2007 Aug; 13(8):544-8. PubMed ID: 17617800
[TBL] [Abstract][Full Text] [Related]
13. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB
Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303
[TBL] [Abstract][Full Text] [Related]
14. Bombesin analogs containing alpha-amino-isobutyric acid with potent anticancer activity.
Prasad S; Mathur A; Gupta N; Jaggi M; Singh AT; Rajendran P; Sanna VK; Datta K; Mukherjee R
J Pept Sci; 2007 Jan; 13(1):54-62. PubMed ID: 17031871
[TBL] [Abstract][Full Text] [Related]
15. Anticancer efficacy of Magainin2 and analogue peptides.
Baker MA; Maloy WL; Zasloff M; Jacob LS
Cancer Res; 1993 Jul; 53(13):3052-7. PubMed ID: 8319212
[TBL] [Abstract][Full Text] [Related]
16. The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent.
Mizejewski GJ
Cancer Biother Radiopharm; 2007 Feb; 22(1):73-98. PubMed ID: 17627416
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological activity of cell-penetrating peptide-modified octreotide analogs.
Xie W; Liu J; Qiu M; Yuan J; Xu A
J Pept Sci; 2010 Feb; 16(2):105-9. PubMed ID: 20014325
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and antimitogenic activities in a peptide from puffball mushroom Calvatia caelata.
Lam YW; Ng TB; Wang HX
Biochem Biophys Res Commun; 2001 Dec; 289(3):744-9. PubMed ID: 11726211
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
20. The disulfide bond arrangement of leukemia inhibitory factor: homology to oncostatin M and structural implications.
Nicola NA; Cross B; Simpson RJ
Biochem Biophys Res Commun; 1993 Jan; 190(1):20-6. PubMed ID: 8422244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
